Browse the evidence

GLP-1 receptor agonists (e.g., Liraglutide 3.0mg) and SGLT2 inhibitors significantly reduce body weight and improve glycemic control in T2D patients, with GLP-1 agonists showing superior weight loss compared to other drug classes.

If lifestyle changes are not enough, ask your doctor about GLP-1 receptor agonists (like Liraglutide) or SGLT2 inhibitors. These drugs help you lose weight and control blood sugar, unlike older diabetes medications that cause weight gain. GLP-1s are particularly effective for weight loss.

High dietary salt, low omega-3 fatty acids, and high trans fatty acids are the dietary risks with the largest mortality effects, causing 102,000, 84,000, and 82,000 deaths respectively.

Reduce sodium intake, increase omega-3 fatty acids (e.g., from seafood), and eliminate trans fats. These three dietary factors are responsible for over 268,000 deaths annually, making them key targets for dietary improvement.

Combining GLP-1 RAs with basal insulin provides superior glycemic management and cardiorenal protection compared to using either therapy alone, while mitigating the side effects of high-dose GLP-1 RAs.

If you are struggling to control your blood sugar with just a GLP-1 shot (like Ozempic) or just basal insulin, combining them is often the most effective strategy. New 'fixed-ratio' combination pens allow you to inject both medications in a single shot. This approach lowers your A1C more effectively than either drug alone, protects your heart and kidneys, and often reduces the side effects (like nausea) associated with high doses of GLP-1 RAs.

Using DSNFs as part of a structured lifestyle intervention (tDNA) leads to sustained weight loss and HbA1c reduction over 6-8 years compared to usual care.

If you have Type 2 Diabetes and struggle with weight, using DSNFs as part of a structured plan (like tDNA) that includes motivational support can lead to significant, long-lasting weight loss and better blood sugar control compared to standard advice alone.

Early weight loss (≥5%) within 12-16 weeks is the only consistent predictor of long-term efficacy for obesity pharmacotherapy in polygenic obesity, justifying the discontinuation of ineffective medications.

When starting a new obesity medication, expect to be evaluated at 12-16 weeks. If you haven't lost at least 5% of your body weight by then, your doctor will likely stop the medication. This is not a failure on your part, but a standard safety and efficacy check to switch to a different treatment.

GLP-1 receptor agonists (GLP1-RA) and SGLT2 inhibitors (SGLT2-i) are effective interventions for obesity-related cardiometabolic complications by reducing body weight and addressing pathophysiological derangements.

If lifestyle changes are insufficient, discuss GLP-1 RAs or SGLT2 inhibitors with your doctor. These medications are now recognized as essential tools for managing obesity and its heart/kidney risks, not just for diabetes.

Bariatric surgery (specifically Sleeve Gastrectomy and Roux-en-Y Gastric Bypass) produces significant, sustained weight loss and metabolic improvements in adults with morbid obesity, with RYGB generally demonstrating superior long-term weight loss and diabetes remission rates compared to SG.

For individuals with a BMI ≥35 (or ≥30 with comorbidities like diabetes), bariatric surgery is the most effective medical intervention for significant, sustained weight loss and metabolic health improvement. Roux-en-Y Gastric Bypass (RYGB) generally offers better long-term weight loss and diabetes remission than Sleeve Gastrectomy (SG), but requires strict lifelong supplementation and monitoring. Surgery is not a first-line option for mild obesity but is critical for morbid obesity where lifestyle changes fail.

Supervised exercise training (SET) is a first-line therapy for chronic symptomatic peripheral artery disease (PAD) that significantly improves walking distance and functional status.

If you have PAD, supervised walking exercise is your primary treatment. Go to a clinic or program where professionals supervise you. Walk until your leg pain is severe (3-4 out of 4), rest until it subsides, then walk again. Do this at least 3 times a week for 30+ minutes. This improves your walking distance and quality of life.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide induce significant weight loss (up to ~15%) in non-diabetic individuals with obesity, primarily by acting on GLP-1 receptors in the brain (specifically the arcuate nucleus and area postrema) to suppress food intake.

GLP-1 receptor agonists like semaglutide (2.4 mg weekly) are highly effective for weight loss in obese, non-diabetic adults, achieving ~15% body weight reduction. They work by suppressing appetite via brain receptors. Be aware of common side effects like nausea and the likelihood of weight regain if treatment stops, suggesting a need for long-term management.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater weight loss than GLP-1RAs alone (e.g., semaglutide) in both diabetic and non-diabetic populations, while potentially reducing nausea through GIP receptor signaling.

Tirzepatide (5-15 mg weekly) is more effective for weight loss than semaglutide in patients with type 2 diabetes, achieving 8.5-12.4% weight loss compared to 6.7% for semaglutide. It works by targeting both GIP and GLP-1 receptors, potentially offering a better side effect profile regarding nausea.

Subcutaneous semaglutide at 2.4 mg once weekly produces clinically significant weight loss (mean 14.9–17.4% reduction) in adults with obesity or overweight, with gastrointestinal side effects being the primary limiting factor.

For adults with obesity, weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle changes leads to substantial weight loss (approx. 15%). The main barrier is gastrointestinal side effects like nausea, which are usually mild and do not prevent weight loss. If injections are not preferred, oral semaglutide is an alternative, though subcutaneous administration may yield slightly greater weight loss.

Subcutaneous semaglutide (0.5-1.0 mg) and oral semaglutide (14 mg) effectively reduce body weight and HbA1c in patients with Type 2 Diabetes, with subcutaneous administration showing greater weight loss than oral administration in indirect comparisons.

For patients with Type 2 Diabetes, both subcutaneous (0.5-1.0 mg weekly) and oral (14 mg daily) semaglutide effectively reduce weight and blood sugar. Subcutaneous administration appears to produce greater weight loss than the oral form, though both are superior to other diabetes medications.

Higher levels of physical activity (PA), cardiorespiratory fitness (CRF), and muscular fitness (MF) are associated with a significantly reduced risk of Type 2 Diabetes incidence and reduced all-cause and cardiovascular mortality in individuals with T2D, independent of body weight.

To prevent Type 2 Diabetes or reduce mortality if you already have it, focus on getting moving. Aim for at least 150 minutes of moderate-intensity physical activity per week. Building cardiorespiratory fitness (like walking briskly or cycling) and muscular strength provides significant health benefits that are independent of whether you lose weight. Reducing time spent sitting is also crucial.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) facilitates the largest reduction in body weight and increases in health-related quality of life (QoL) among Type 2 Diabetes medications.

If weight loss and quality of life are your primary goals, Tirzepatide is the most effective medication identified in this analysis. It offers greater weight reduction and QoL improvements than standard GLP-1 RAs, though it may cause gastrointestinal side effects.

GLP-1 receptor agonists (GLP-1RA) such as semaglutide and liraglutide produce significant weight loss (≥10%) and cardiovascular benefits in adults with obesity.

GLP-1 receptor agonists like semaglutide are highly effective for weight loss, often achieving 10% or more body weight reduction, and also provide cardiovascular benefits. These medications are available in both injectable and oral forms, offering flexibility for long-term management of obesity.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial, dose-dependent weight loss in adults with obesity (mean 15-21% over 72 weeks) and superior glycemic control compared to placebo and other GLP-1 agonists.

Tirzepatide is a once-weekly injection that targets two gut hormones (GIP and GLP-1) to reduce appetite and improve blood sugar. In clinical trials, it led to an average weight loss of 15-21% over 72 weeks, significantly outperforming placebo and other GLP-1 drugs like Semaglutide. It is prescribed for adults with obesity (BMI ≥30, or ≥27 with comorbidities) and requires a slow dose escalation to manage gastrointestinal side effects.

GLP-1 and GIP agonists (e.g., semaglutide) significantly improve glycemic control, promote weight loss, and provide cardiovascular and renal protection in patients with obesity and type 2 diabetes.

If you have obesity and type 2 diabetes, ask your doctor about GLP-1/GIP agonists. These drugs treat the underlying biology, help you lose weight, and protect your heart and kidneys.

Semaglutide 2.4 mg administered once weekly via subcutaneous injection significantly reduces body weight in adults with obesity or overweight when used as an adjunct to lifestyle modifications.

If you have obesity or overweight with a related health condition, ask your doctor about Semaglutide 2.4 mg. It is taken as a once-weekly injection alongside diet and exercise. Expect significant weight loss (around 15% in trials), but be prepared for temporary stomach issues like nausea, which usually get better over time.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) and SGLT2 inhibitors provide cardiovascular and renal benefits independent of glycemic control, with GLP-1 RAs being preferred for obesity/T2D and SGLT2 inhibitors for T2D with heart failure.

If you have T2D and obesity, ask your doctor about GLP-1 agonists (like Semaglutide or Liraglutide). They help with weight loss and protect your heart and kidneys, even if your blood sugar is already controlled. If you also have heart failure, SGLT2 inhibitors might be better.

Replacing saturated fatty acids with unsaturated fatty acids (specifically cis-PUFAs or cis-MUFAs) significantly decreases total cholesterol and LDL cholesterol levels.

To lower LDL cholesterol, replace saturated fats with unsaturated fats. Substituting just 1% of your daily energy from saturated fat with polyunsaturated fat (like oils from nuts/seeds/fish) can lower LDL by ~2 mg/dl.

GLP-1 receptor agonists lower plasma glucose and suppress appetite, providing significant benefits for glycemic control and weight loss in type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, GLP-1 receptor agonists are a proven, first-line treatment option that effectively lowers blood sugar and aids weight loss. Discuss these options with your healthcare provider to see if they are appropriate for your specific health profile.

Liraglutide 3.0 mg, a GLP-1 analogue, promotes weight loss and improves metabolic parameters through mechanisms involving hypothalamic energy balance regulation, glucose-dependent insulin stimulation, and slowed gastric emptying.

Liraglutide 3.0 mg works by mimicking a natural hormone that regulates hunger, insulin, and digestion. It is taken as a daily injection, starting at a low dose and increasing weekly to reduce side effects like nausea. It is contraindicated for those with specific thyroid cancer histories.

Adherence to healthy dietary patterns, specifically increasing intake of fruits, vegetables, whole grains, fish, and legumes while limiting salt, saturated fats, trans fats, and processed meats, significantly reduces cardiovascular disease morbidity and mortality.

Eat more plants, fish, and whole grains. Eat less salt, bad fats, and processed meats. This is the foundation of heart health.

Specific dietary models, namely the Mediterranean diet and the DASH (Dietary Approaches to Stop Hypertension) diet, are effective for both primary and secondary prevention of cardiovascular diseases.

Adopt either the Mediterranean or DASH dietary pattern. Focus on plant-based foods, healthy fats, and lean proteins.